GeneFerm Biotechnology Co., Ltd. (TPEX:1796)
30.15
+0.10 (0.33%)
Sep 8, 2026, 11:19 AM CST
GeneFerm Biotechnology Revenue
GeneFerm Biotechnology had revenue of 168.93M TWD in the quarter ending June 30, 2026, with 0.64% growth. This brings the company's revenue in the last twelve months to 664.94M, up 7.05% year-over-year. In the year 2025, GeneFerm Biotechnology had annual revenue of 677.10M with 29.92% growth.
Revenue (ttm)
664.94M
Revenue Growth
+7.05%
P/S Ratio
1.87
Revenue / Employee
4.62M
Employees
144
Market Cap
1.25B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 677.10M | 155.94M | 29.92% |
| Dec 31, 2024 | 521.16M | -272.61M | -34.34% |
| Dec 31, 2023 | 793.77M | 159.81M | 25.21% |
| Dec 31, 2022 | 633.96M | 111.63M | 21.37% |
| Dec 31, 2021 | 522.33M | 154.03M | 41.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.40B |
| Prince Pharmaceutical | 1.22B |
| Excelsior Biopharma | 936.92M |
| Anxo Pharmaceutical | 878.88M |
| DV Biomed | 795.19M |
| Winston Medical Supply | 632.80M |
| Johnson Chemical Pharmaceutical Works | 577.93M |
| Mediera | 195.89M |